Other · developed by Sanofi
Lunsekimig (SAR443765) is an investigational agent given as a subcutaneous injection solution. It is studied in chronic rhinosinusitis with nasal polyps.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07190209 | Phase 3 | Chronic Obstructive Pulmonary Disease | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Rhinosinusitis With Nasal Polyps
Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →